Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription 20.06.2022 1 Am J Ind Med 2 Am J Pathol 2 Ann Surg Oncol 1 Ann Thorac Surg 15 Arch Bronconeumol 4 BMC Cancer 2 Cancer Lett 1 Cancer Res 3 Chest 3 Clin Cancer Res 4 Clin Lung Cancer 3 Eur J Cancer 2 J Cancer Res Clin Oncol 1 J Natl Cancer Inst 1 J Nucl Med 1 J Thorac Cardiovasc Surg 1 J Thorac Oncol 5 Lung Cancer 2 Oncogene 2 Oncologist 1 PLoS One 2 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Ind Med

1. ALMEIDA GC, Santos UP, Parente YDM, Colares PFB, et al
   Mesothelioma in situ with regressive malignant pleural effusion and an unexpected evolution: A case report.
   Am J Ind Med. 2022;65:620-623.
   PubMed         Abstract available
   
   

   
   Am J Pathol

2. MASAWA M, Sato-Yazawa H, Kashiwagi K, Ishii J, et al
   REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
   Am J Pathol. 2022;192:847-861.
   PubMed         Abstract available
   
   
3. ZHOU Y, Chang M, Wang N, Zhuang Y, et al
   Phosphatidylserine-Specific Phospholipase A1 Limits Aggressiveness of Lung Adenocarcinoma by Lysophosphatidylserine and Protein Kinase A-Dependent Pathway.
   Am J Pathol. 2022;192:970-983.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. USHITANI Y, Shimada Y
   ASO Author Reflections: Management to Prevent Postoperative Sarcopenia in Patients with Lung Cancer.
   Ann Surg Oncol. 2022 Jun 14. pii: 10.1245/s10434-022-12026.
   PubMed        
   
   
5. BAILEY J, Van Haren RM
   Complementary Roles of Screening and Nodule Programs for Early Detection of Lung Cancer in Diverse Populations.
   Ann Surg Oncol. 2022 Jun 12. pii: 10.1245/s10434-022-11943.
   PubMed        
   
   

   
   Ann Thorac Surg

6. LINHARDT FC, Santer P, Xu X, Gangadharan S, et al
   Reintubation after lung cancer resection. Development and external validation of a predictive score.
   Ann Thorac Surg. 2022 Jun 8. pii: S0003-4975(22)00804.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

7. LAINEZ RAMOS-BOSSINI AJ, Ruiz Carazo E, Lopez Milena G
   Double fistula after cavitation of lung adenocarcinoma treated by microwave thermal ablation. An exceedingly rare complication.
   Arch Bronconeumol. 2021;57:546.
   PubMed        
   
   
8. AGUINAGALDE B, Insausti A, Lopez I, Sanchez L, et al
   VATS lobectomy morbidity and mortality is lower in patients with the same ppoDLCO: Analysis of the database of the Spanish Video-Assisted Thoracic Surgery Group.
   Arch Bronconeumol. 2021;57:750-756.
   PubMed         Abstract available
   
   
9. NAVARRO ESTEVA J, Travieso Betancor J, Freixinet Gilart J
   Right Vocal Cord Paralysis Due to Lymphatic Spread of Lung Cancer.
   Arch Bronconeumol. 2021;57:770.
   PubMed        
   
   
10. MARTINEZ BARROSO K, Borregon Rivilla M, Mazariegos Rubi M, Medina Martinez J, et al
    Severe lung and pleural involvement due to osteosarcoma in a 24 year woman. The most aggressive visceral presentation of a bone tumor.
    Arch Bronconeumol. 2021;57:771.
    PubMed        
    
    
11. DE-TORRES JP, Wisnivesky JP
    Lung Cancer Screening in Patients With Chronic Obstructive Pulmonary Disease: Do the Benefits Outweigh the Risks?
    Arch Bronconeumol. 2021;57:679-680.
    PubMed        
    
    
12. BELLO S, Vengoechea JJ, Ponce-Alonso M, Figueredo AL, et al
    Core Microbiota in Central Lung Cancer With Streptococcal Enrichment as a Possible Diagnostic Marker.
    Arch Bronconeumol. 2021;57:681-689.
    PubMed         Abstract available
    
    
13. FRAILE OLIVERO CA, Pardina Solano MA, Milla Collado L
    Intraoperatory diagnosis of partial anomalous pulmonary venous return during pulmonary resection surgery in a non-small cell lung cancer patient.
    Arch Bronconeumol. 2021;57:703.
    PubMed        
    
    
14. SOLER-SEMPERE MJ, Alvarez-Fernandez MO, Padilla-Navas I, Cabezas-Macian M, et al
    Merkel cell carcinoma with pleural effusion.
    Arch Bronconeumol. 2021;57:715-717.
    PubMed        
    
    
15. TRAVIER N, Fu M, Romaguera A, Martin-Cantera C, et al
    6-Year Risk of Developing Lung Cancer in Spain: Analysis by Autonomous Communities.
    Arch Bronconeumol. 2021;57:521-527.
    PubMed         Abstract available
    
    
16. CARRICO F, Alves RM, Luis F
    Foreign Body Aspiration Simulating Lung Cancer.
    Arch Bronconeumol. 2021;57:540.
    PubMed        
    
    
17. KAOUS M, Bashoura L, Faiz SA
    Gelatinous Pleural Fluid With Mesothelioma.
    Arch Bronconeumol. 2021;57:543.
    PubMed        
    
    
18. TEIXEIRA E SILVA TORRES PP, Ximenes Salustiano L, Marchiori E
    DIPNECH: When Computed Tomography May Suggest the Diagnosis.
    Arch Bronconeumol. 2021;57:544.
    PubMed        
    
    
19. RUANO-RAVINA A, Cameselle-Lago C, Torres-Duran M, Pando-Sandoval A, et al
    Indoor Radon Exposure and COPD, Synergic Association? A Multicentric, Hospital-Based Case-Control Study in a Radon-Prone Area.
    Arch Bronconeumol. 2021;57:630-636.
    PubMed         Abstract available
    
    
20. DIAS CUNHA A, Sousa M, Sousa P
    Atypical Metastasis of Lung Adenocarcinoma.
    Arch Bronconeumol. 2021;57:650.
    PubMed        
    
    
21. SALAMO O, Cherian SV, Estrada-Y-Martin RM
    88-Year-Old Woman With an Incidental Lung Mass.
    Arch Bronconeumol. 2021;57:651.
    PubMed        
    
    

    
    BMC Cancer

22. GEN S, Tanaka I, Morise M, Koyama J, et al
    Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
    BMC Cancer. 2022;22:654.
    PubMed         Abstract available
    
    
23. DENG S, Jiang Z, Cao Y, Gu J, et al
    Development and validation of a prognostic scoring system for patients with colorectal cancer hepato-pulmonary metastasis: a retrospective study.
    BMC Cancer. 2022;22:643.
    PubMed         Abstract available
    
    
24. CALVET L, Dos-Santos O, Spanakis E, Jean-Baptiste V, et al
    YAP1 is essential for malignant mesothelioma tumor maintenance.
    BMC Cancer. 2022;22:639.
    PubMed         Abstract available
    
    
25. JIANG J, Lu Y, Zhang F, Pan T, et al
    Semaphorin 4B promotes tumor progression and associates with immune infiltrates in lung adenocarcinoma.
    BMC Cancer. 2022;22:632.
    PubMed         Abstract available
    
    

    
    Cancer Lett

26. CHEN B, Song Y, Zhan Y, Zhou S, et al
    Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway.
    Cancer Lett. 2022 Jun 11:215783. doi: 10.1016/j.canlet.2022.215783.
    PubMed         Abstract available
    
    
27. LI S, Qu Y, Liu L, Zhang X, et al
    Proteomic analysis of plasma-derived exosomes identifies biomarkers that distinguish brain and liver metastasis in lung cancer patients.
    Cancer Lett. 2022 Jun 9:215782. doi: 10.1016/j.canlet.2022.215782.
    PubMed         Abstract available
    
    

    
    Cancer Res

28. CHOI YJ, Kim DS, Hoon Sung Y, Kim DH, et al
    The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.
    Cancer Res. 2022 Jun 14. pii: 704898. doi: 10.1158/0008-5472.CAN-22-0394.
    PubMed         Abstract available
    
    

    
    Chest

29. STELIGA MA
    Smoking Cessation Impacts Survival: A Necessary Component of Cancer Care.
    Chest. 2022;161:1442-1443.
    PubMed        
    
    
30. BALDI BG, Radzikowska E, Cottin V, Dilling DF, et al
    COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition.
    Chest. 2022;161:1589-1593.
    PubMed        
    
    
31. LASHARI BH, Kumaran M, Aneja A, Bull T, et al
    BEYOND CLOTS IN THE PULMONARY CIRCULATION; PULMONARY ARTERY TUMORS MIMICKING PULMONARY EMBOLISM.
    Chest. 2022 Jan 15. pii: S0012-3692(22)00048-4. doi: 10.1016/j.chest.2022.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

32. TAKEMOTO A, Takagi S, Ukaji T, Gyobu N, et al
    Targeting Podoplanin for the Treatment of Osteosarcoma.
    Clin Cancer Res. 2022;28:2633-2645.
    PubMed         Abstract available
    
    
33. MURCIANO-GOROFF YR, Harada G, Drilon A
    An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers.
    Clin Cancer Res. 2022;28:2477-2479.
    PubMed         Abstract available
    
    
34. GUAN S, Chen X, Chen Y, Xie W, et al
    FOXM1 variant contributes to gefitinib resistance via activating wnt/beta-catenin signal pathway in non-small cell lung cancer patients.
    Clin Cancer Res. 2022 Jun 13. pii: 704872. doi: 10.1158/1078-0432.CCR-22-0791.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

35. SCHNEIDER CS, Hatic H, Das D, Cardan RA, et al
    Patterns of Failure and Optimal Treatment Paradigm for Large, Inoperable, Node-Negative Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00103.
    PubMed         Abstract available
    
    
36. FUKUSHIMA T, Oyamada Y, Ikemura S, Nukaga S, et al
    Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00099.
    PubMed         Abstract available
    
    
37. BIRONZO P, Primo L, Novello S, Righi L, et al
    Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00100.
    PubMed         Abstract available
    
    
38. SIRGI Y, Krochmal R, Fleury CM, Holmes M, et al
    Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment.
    Clin Lung Cancer. 2022 May 20. pii: S1525-7304(22)00107.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

39. BRYANT AK, Sankar K, Zhao L, Strohbehn GW, et al
    De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.
    Eur J Cancer. 2022;171:55-63.
    PubMed         Abstract available
    
    
40. CUI W, Milner-Watts C, O'Sullivan H, Lyons H, et al
    Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
    Eur J Cancer. 2022;171:44-54.
    PubMed         Abstract available
    
    
41. WANG C, Hu Q, Sun Y, Yu F, et al
    Complete pathological remission after neoadjuvant ensartinib in patients with locally advanced lung adenocarcinoma and with CTLC-ALK and ALK-DHX8 rearrangements.
    Eur J Cancer. 2022;169:131-134.
    PubMed        
    
    

    
    J Cancer Res Clin Oncol

42. KOWALSKI B, Valaperti A, Bezel P, Steiner UC, et al
    Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study.
    J Cancer Res Clin Oncol. 2022;148:1711-1720.
    PubMed         Abstract available
    
    
43. GURBUZ M, Kutlu Y, Akkus E, Koksoy EB, et al
    Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.
    J Cancer Res Clin Oncol. 2022 Jun 11. pii: 10.1007/s00432-022-04087.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

44. CASTILHO JL, Bian A, Jenkins CA, Shepherd BE, et al
    CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.
    J Natl Cancer Inst. 2022;114:854-862.
    PubMed         Abstract available
    
    

    
    J Nucl Med

45. STERBIS E, Liang R, Trivedi P, Kwak J, et al
    Lack of adherence to guideline-based imaging prior to subsequent radiation in patients with non-small cell lung cancer: Impact on patient outcomes.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264131. doi: 10.2967/jnumed.122.264131.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

46. FURRER K, Weder W, Eboulet EI, Betticher D, et al
    Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
    J Thorac Cardiovasc Surg. 2022 Apr 18. pii: S0022-5223(22)00403.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

47. NGUYEN EM, Taniguchi H, Chan JM, Zhan YA, et al
    Targeting LSD1 rescues MHC class I antigen presentation and overcomes PD-L1 blockade resistance in small cell lung cancer.
    J Thorac Oncol. 2022 Jun 9. pii: S1556-0864(22)00273.
    PubMed         Abstract available
    
    

    
    Lung Cancer

48. CUPPENS K, Baas P, Geerdens E, Cruys B, et al
    HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
    Lung Cancer. 2022;170:1-10.
    PubMed         Abstract available
    
    
49. PILOTTO S, Avancini A, Menis J, Sperduti I, et al
    Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey.
    Lung Cancer. 2022;169:94-101.
    PubMed         Abstract available
    
    
50. RIUDAVETS M, Cascetta P, Planchard D
    Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
    Lung Cancer. 2022;169:102-114.
    PubMed         Abstract available
    
    
51. GROVER H, King W, Bhattarai N, Moloney E, et al
    Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography.
    Lung Cancer. 2022;170:20-33.
    PubMed         Abstract available
    
    
52. SIGEL K, Yin Kong C, Leiter A, Kale M, et al
    Assessment of treatment strategies for stage I non-small cell lung cancer in patients with comorbidities.
    Lung Cancer. 2022;170:34-40.
    PubMed         Abstract available
    
    

    
    Oncogene

53. UESHIMA S, Fang J
    Histone H3K9 methyltransferase SETDB1 augments invadopodia formation to promote tumor metastasis.
    Oncogene. 2022;41:3370-3380.
    PubMed         Abstract available
    
    
54. GALLARDO A, Molina A, Asenjo HG, Lopez-Onieva L, et al
    EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization.
    Oncogene. 2022 Jun 9. pii: 10.1038/s41388-022-02375.
    PubMed         Abstract available
    
    

    
    Oncologist

55. MACK PC, Klein MI, Ayers KL, Zhou X, et al
    Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Oncologist. 2022;27:476-486.
    PubMed         Abstract available
    
    
56. GANTZER J, Davidson G, Vokshi B, Weingertner N, et al
    Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:501-511.
    PubMed         Abstract available
    
    

    
    PLoS One

57. SPINI A, Rosellini P, Bellan C, Furiesi F, et al
    Development and validation of a case-finding algorithm for the identification of non-small cell lung cancers in a region-wide Italian pathology registry.
    PLoS One. 2022;17:e0269232.
    PubMed         Abstract available
    
    

    
    Thorax

58. KANABAR SS, Tiwari A, Soran V, Balendran P, et al
    Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review.
    Thorax. 2022 Jun 10. pii: thoraxjnl-2020-215614.
    PubMed         Abstract available
    
    
59. IM Y, Chung MP, Lee KS, Han J, et al
    Impact of interstitial lung abnormalities on postoperative pulmonary complications and survival of lung cancer.
    Thorax. 2022 Jun 10. pii: thoraxjnl-2021-218055.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: